Multiprofile Hospital For Active Treatment Dr. Hristo Stambolski EOOD — Clinical Trial Site

10 Registered trials

3 Currently recruiting

Organisation

Multiprofile Hospital For Active Treatment Dr. Hristo Stambolski EOOD

Location

Kazanlik, Bulgaria

Identifier

ORG-100050601

Address

Ulitsa Starozagorska 16, 6102, Bulgaria

Departments

Department of Psychiatry
Psychiatry

Clinical trials at this site (10)

Search interface

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) - X-CE… Pending

2025-522775-29-00 Depressive episodes associated with Bipolar disorder I 5
An Open-label Study of Azetukalner in Bipolar I or II Depression Pending

2025-522872-10-00 Depressive episodes associated with Bipolar disorder I 5
A Phase 2 Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with Schizophrenia (STAR-1) Pending

2025-524058-32-00 Schizophrenia 4
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia Recruiting

2025-521868-35-00 Schizophrenia 4 2026-04-08
DT-101 in Adults with Major Depressive Disorder Recruiting

2025-522784-15-00 Major Depressive Disorder 4 2026-03-24
A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLU… Recruiting

2023-507372-42-00 Schizophrenia 4 2021-09-20
A study to assess the efficacy and safety of lumateperone in patients with Bipolar Mania Ended

2024-513037-20-00 Bipolar I Disorder (Bipolar Mania) 5 2024-12-19
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a… Ended

2024-513104-34-00 Major Depressive Disorder 4 2024-11-25
A rollover study for subjects that complete KAR-012 trial, to assess Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with … Ended

2024-510773-20-00 Schizophrenia 5 2023-06-12
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) Ended

2024-510770-25-00 Schizophrenia 5 2023-03-22